Results 151 to 160 of about 1,264,620 (412)

Lymphoma and Pregnancy [PDF]

open access: yesJAMA Oncology, 2017
Maria-Jesus Nambo   +2 more
openaire   +5 more sources

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

open access: yes, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M.   +3 more
core   +1 more source

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

open access: yesBlood, 2016
Uniformly adopted response criteria are essential for assessment of therapies incorporating conventional chemotherapy and chemoimmunotherapy regimens. Recently, immunomodulatory agents, such as immune checkpoint inhibitors, have demonstrated impressive ...
B. Cheson   +8 more
semanticscholar   +1 more source

Machine stability and dosimetry for ultra‐high dose rate FLASH radiotherapy human clinical protocol

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Background The FLASH effect, induced by ultra‐high dose rate (UHDR) irradiations, offers the potential to spare normal tissue while effectively treating tumors. It is important to achieve precise and accurate dose delivery and to establish reliable detector systems, particularly for clinical trials needed to help the clinical transfer of FLASH‐
Patrik Gonçalves Jorge   +9 more
wiley   +1 more source

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma

open access: yesBiomarker Research
Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL).
Vivian Jiang   +9 more
doaj   +1 more source

Mantle Cell Lymphoma.

open access: yesJournal of Clinical Oncology, 2016
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy ...
C. Cheah, John F Seymour, Michael L Wang
semanticscholar   +1 more source

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ...
Young Nam Kwon   +24 more
wiley   +1 more source

Strategies for increasing accrual in cancer clinical trials: What is the evidence?

open access: yesCancer Medicine
Introduction Despite the importance of clinical trial participation among cancer patients, few participate—and even fewer patients from ethnic and racial minoritized groups.
Margo Michaels   +9 more
doaj   +1 more source

Autologous hematopoietic stem cell transplantation as first‐line consolidation therapy can improve the prognosis of diffuse large B‐cell lymphoma with high expression of MYC protein

open access: yesKaohsiung Journal of Medical Sciences, 2019
Myc‐positive diffuse large B‐cell lymphoma has lower curative efficacy and long‐term survival than its negative counterpart, even when treated with R‐CHOP regimen.
Kai Hu   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy